News & Views
Raised Capital to Progress Therapeutics Pipeline
Mar 29 2016
After raising NOK212 million (c.$25 million) in a private placement from existing shareholders, including Investinor AS and Meteva AS, BerGenBio will use funds to progress the Company’s pipeline of innovative cancer therapeutics, in particular its lead asset BGB324, a first-in-class Axl kinase inhibitor.
BGB324 is currently being evaluated in a Phase 1b trial in patients with acute myeloid leukaemia (AML) and also in a Phase 1b trial in patients with Stage IIIb and Stage IV non-small cell lung cancer (NSCLC). BGB324 is said to block the epithelial-mesenchymal transition (EMT), which is a key driver in immune evasion, drug-resistance and metastasis in cancers.
Richard Godfrey, Chief Executive Officer of BerGenBio, commented:
“We are very pleased to have received this new investment from our shareholders at this important time in the Company's development and would like to thank them for their continued support. The proceeds will be used primarily to support the ongoing clinical and commercial development of our lead asset BGB324, as we prepare to open several Phase 2 combination trials.”
BerGenBio also announces the following changes to its Board of Directors. John Barrie Ward and David Wilson have stepped down from the Board. Stein H. Annexstad, Kari Grønås and Sveinung Hole have been appointed as new Non-Executive Directors. Susan Foden has stepped down as Chair but remains a Non-Executive Director, while Hilde Furberg has been appointed as Chair of the Board of Directors.
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China